$BJDX
Bluejay Diagnostics, Inc. Stock $bjdx

$bjdx Overview Financials Valuation SEC Filings Company Website

2024 Q3 Form 10-Q Financial Statement

#000121390024069110 Filed on August 14, 2024

Income Statement

Concept	2024 Q3	2024 Q2
Revenue
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin		$862.8K
YoY Change		-29.71%
% of Gross Profit
Research & Development	$551.7K	$1.032M
YoY Change	-60.52%	-38.41%
% of Gross Profit
Depreciation & Amortization		$18.47K
YoY Change		-92.7%
% of Gross Profit
Operating Expenses	$1.362M	$1.895M
YoY Change	-41.84%	-34.73%
Operating Profit	-$1.362M	-$1.895M
YoY Change	-41.84%	-34.73%
Interest Expense	$185.9K
YoY Change
% of Operating Profit
Other Income/Expense, Net	-$120.4K	-$580.1K
YoY Change	-378.37%	-741.85%
Pretax Income
YoY Change
Income Tax
% Of Pretax Income
Net Earnings	-$1.482M	-$2.475M
YoY Change	-35.51%	-12.01%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.16	-$5.12
Diluted Earnings Per Share	-$0.16	-$5.12
COMMON SHARES
Basic Shares Outstanding	6.252M shares	2.904M shares
Diluted Shares Outstanding	9.556M shares	483.2K shares

Balance Sheet

Concept	2024 Q3	2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments		$8.058M
YoY Change		58.0%
Cash & Equivalents	$5.800M	$8.058M
Short-Term Investments
Other Short-Term Assets		$960.0K
YoY Change		-35.2%
Inventory
Prepaid Expenses
Receivables
Other Receivables	$8.315K	$30.61K
Total Short-Term Assets	$6.568M	$9.018M
YoY Change	0.61%	37.02%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.535M	$1.553M
YoY Change	16.11%	6.07%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$23.60K	$24.41K
YoY Change	-21.1%	-22.95%
Total Long-Term Assets	$1.786M	$1.841M
YoY Change	3.89%	-2.93%
TOTAL ASSETS
Total Short-Term Assets	$6.568M	$9.018M
Total Long-Term Assets	$1.786M	$1.841M
Total Assets	$8.353M	$10.86M
YoY Change	1.3%	28.08%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$316.7K	$490.1K
YoY Change	-58.11%	80.51%
Accrued Expenses		$1.415M
YoY Change		1.59%
Deferred Revenue
YoY Change
Short-Term Debt		$147.4K
YoY Change
Long-Term Debt Due		$4.810K
YoY Change		0.0%
Total Short-Term Liabilities	$1.000M	$2.057M
YoY Change	-64.29%	12.24%
LONG-TERM LIABILITIES
Long-Term Debt		$10.48K
YoY Change		-25.67%
Other Long-Term Liabilities	$9.530K	$10.48K
YoY Change	-27.91%	-25.72%
Total Long-Term Liabilities	$9.530K	$10.48K
YoY Change	-27.91%	-25.72%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.000M	$2.057M
Total Long-Term Liabilities	$9.530K	$10.48K
Total Liabilities	$1.189M	$2.218M
YoY Change	-60.8%	5.53%
SHAREHOLDERS EQUITY
Retained Earnings	-$33.24M	-$31.75M
YoY Change	34.84%	42.08%
Common Stock	$40.40M	$40.40M
YoY Change	35.3%	39603733.33%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$7.164M	$8.641M
YoY Change
Total Liabilities & Shareholders Equity	$8.353M	$10.86M
YoY Change	1.3%	28.08%

Cashflow Statement

Concept	2024 Q3	2024 Q2
OPERATING ACTIVITIES
Net Income	-$1.482M	-$2.475M
YoY Change	-35.51%	-12.01%
Depreciation, Depletion And Amortization		$18.47K
YoY Change		-92.7%
Cash From Operating Activities		-$1.854M
YoY Change		25.44%
INVESTING ACTIVITIES
Capital Expenditures		$270.0K
YoY Change		34.26%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities		-$270.0K
YoY Change		34.26%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities		7.521M
YoY Change		-280728.73%
NET CHANGE
Cash From Operating Activities		-1.854M
Cash From Investing Activities		-270.0K
Cash From Financing Activities		7.521M
Net Change In Cash		5.397M
YoY Change		-420.98%
FREE CASH FLOW
Cash From Operating Activities		-$1.854M
Capital Expenditures		$270.0K
Free Cash Flow		-$2.124M
YoY Change		26.49%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-12.35
CY2024Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-5.12
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	127881	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	389042	shares
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2024-06-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-41031
	dei	Entity Registrant Name EntityRegistrantName	Bluejay Diagnostics, Inc.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	47-3552922
	dei	Entity Address Address Line1 EntityAddressAddressLine1	360 Massachusetts Avenue
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 203
	dei	Entity Address City Or Town EntityAddressCityOrTown	Acton
	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	01720
	dei	City Area Code CityAreaCode	(844)
	dei	Local Phone Number LocalPhoneNumber	327-7078
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Security12b Title Security12bTitle	Common Stock
	dei	Trading Symbol TradingSymbol	BJDX
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Shell Company EntityShellCompany	false
CY2024Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	6252192	shares
CY2024Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8058415	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2208516	usd
CY2024Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	959993	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	747263	usd
CY2023Q4	us-gaap	Deferred Offering Costs DeferredOfferingCosts	265081	usd
CY2024Q2	us-gaap	Assets Current AssetsCurrent	9018408	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	3220860	usd
CY2024Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1552994	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1285741	usd
CY2024Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	263402	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	333267	usd
CY2024Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	24407	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	28663	usd
CY2024Q2	us-gaap	Assets Assets	10859211	usd
CY2023Q4	us-gaap	Assets Assets	4868531	usd
CY2024Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	490056	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	491474	usd
CY2024Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	128633	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	162990	usd
CY2024Q2	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	1290753	usd
CY2023Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	1116911	usd
CY2024Q2	us-gaap	Notes Payable Current NotesPayableCurrent	147440	usd
CY2024Q2	us-gaap	Liabilities Current LiabilitiesCurrent	2056882	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1771375	usd
CY2024Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	150777	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	189987	usd
CY2024Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	10477	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	12321	usd
CY2024Q2	us-gaap	Liabilities Liabilities	2218136	usd
CY2023Q4	us-gaap	Liabilities Liabilities	1973683	usd
CY2024Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	7500000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	7500000	shares
CY2024Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	2584058	shares
CY2024Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2584058	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	154893	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	154893	shares
CY2024Q2	us-gaap	Common Stock Value CommonStockValue	258	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	16	usd
CY2024Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	40395652	usd
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	29845822	usd
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-31754835	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-26950990	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	8641075	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	2894848	usd
CY2024Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	10859211	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	4868531	usd
CY2024Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1032474	usd
CY2023Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1676256	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2366019	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3030805	usd
CY2024Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	862482	usd
CY2023Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1073103	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1950618	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2250080	usd
CY2024Q2	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	305	usd
CY2023Q2	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	154329	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	6728	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	302375	usd
CY2024Q2	us-gaap	Operating Expenses OperatingExpenses	1895261	usd
CY2023Q2	us-gaap	Operating Expenses OperatingExpenses	2903688	usd
	us-gaap	Operating Expenses OperatingExpenses	4323365	usd
	us-gaap	Operating Expenses OperatingExpenses	5583260	usd
CY2024Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-1895261	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-2903688	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-4323365	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-5583260	usd
CY2024Q2	us-gaap	Investment Income Investment Expense InvestmentIncomeInvestmentExpense	626471	usd
CY2023Q2	us-gaap	Investment Income Investment Expense InvestmentIncomeInvestmentExpense	336	usd
	us-gaap	Investment Income Investment Expense InvestmentIncomeInvestmentExpense	631689	usd
	us-gaap	Investment Income Investment Expense InvestmentIncomeInvestmentExpense	685	usd
CY2024Q2	us-gaap	Other Income OtherIncome	46352	usd
CY2023Q2	us-gaap	Other Income OtherIncome	90719	usd
	us-gaap	Other Income OtherIncome	151209	usd
	us-gaap	Other Income OtherIncome	230797	usd
CY2024Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-580119	usd
CY2023Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	90383	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-480480	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	230112	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-2475380	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-2813305	usd
	us-gaap	Net Income Loss NetIncomeLoss	-4803845	usd
	us-gaap	Net Income Loss NetIncomeLoss	-5353148	usd
CY2024Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-5.12
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-22
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-12.35
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-41.95
CY2024Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	483164	shares
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	127881	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	389042	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	127608	shares
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	2894848	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	11874	usd
CY2024Q1	bjdx	Stock Issued During Period Issuanceof Common Stockand Prefunded Warrantsnetofissuancecosts StockIssuedDuringPeriodIssuanceofCommonStockandPrefundedWarrantsnetofissuancecosts	2788969	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-2328465	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	3367226	usd
CY2024Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	6010	usd
CY2024Q2	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	307563	usd
CY2024Q2	bjdx	Stock Issued During Period Value Issuance Of Common Stock In Connection With June2024 Offering Net Of Issuance Costs Of13 StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithJune2024OfferingNetOfIssuanceCostsOf13	7435656	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-2475380	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	8641075	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	11541273	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	54730	usd
CY2023Q1	bjdx	Stock Issued During Period Value Issuance Of Common Stock To Settle Accrued Bonus StockIssuedDuringPeriodValueIssuanceOfCommonStockToSettleAccruedBonus	107235	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-2539843	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	9163395	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	27702	usd
CY2023Q2	bjdx	Stock Issued During Period Restricted Stock Units Tax Value StockIssuedDuringPeriodRestrictedStockUnitsTaxValue	-1453	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-2813305	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	6376339	usd
	us-gaap	Net Income Loss NetIncomeLoss	-4803845	usd
	us-gaap	Net Income Loss NetIncomeLoss	-5353148	usd
	us-gaap	Depreciation Depreciation	38178	usd
	us-gaap	Depreciation Depreciation	373192	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	17884	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	247293	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	69865	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	80655	usd
	us-gaap	Other Noncash Expense OtherNoncashExpense	571	usd
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	621904	usd
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	1787	usd
	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	-265081	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	212730	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-191968	usd
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-4256	usd
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-3536	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-214072	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-429590	usd
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-41625	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	104851	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	472980	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4149682	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4411327	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	305431	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	541774	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-305431	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-541774	usd
	us-gaap	Proceeds From Issuance Of Unsecured Debt ProceedsFromIssuanceOfUnsecuredDebt	287580	usd
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	2000000	usd
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	1917210	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	12069075	usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1844450	usd
	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	2403	usd
	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	2403	usd
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	59079	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	10305012	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-61482	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	5849899	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-5014583	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2208516	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	10114990	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	8058415	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5100407	usd
	bjdx	Fair Value Of Common Stock Issued In Connection With Notes Payable FairValueOfCommonStockIssuedInConnectionWithNotesPayable	307563	usd
	us-gaap	Noncash Or Part Noncash Acquisition Other Assets Acquired1 NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1	65260	usd
	us-gaap	Nature Of Operations NatureOfOperations	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>1. NATURE OF OPERATIONS AND BASIS OF PRESENTATION</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Business</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Bluejay Diagnostics, Inc. (“Bluejay” or the “Company”) is a medical diagnostics company developing rapid tests using whole blood on our Symphony technology platform (“Symphony”) to improve patient outcomes in critical care settings. The Company’s Symphony platform is a combination of Bluejay’s intellectual property (“IP”) and exclusively licensed and patented IP that consists of a mobile device and single-use test cartridges that if cleared, authorized, or approved by the U.S. Food and Drug Administration (the “FDA”), can provide a solution to a significant market need in the United States. Clinical trials indicate the Symphony device produces results in less than 20 minutes for intensive care units and emergency rooms, where rapid and reliable results are required.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Bluejay’s first product, the Symphony IL-6 test, is for the monitoring of disease progression in critical care settings. IL-6 is a clinically established inflammatory biomarker, considered a ‘first-responder,’ for assessment of severity of infection and inflammation across many disease indications, including sepsis. A current challenge of healthcare professionals is the excessive time and cost associated determining a patient’s level of severity at triage and the Symphony IL-6 test has the ability to consistently monitor this critical care biomarker with rapid results.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the future Bluejay plans to develop additional tests for Symphony including two cardiac biomarkers (hsTNT and NT pro-BNP), as well as other tests using the Symphony platform. The Company does not yet have regulatory clearance for its Symphony products, and its Symphony products will need to receive regulatory authorization from the FDA in order to be marketed as a diagnostic product in the United States.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the future, Bluejay also plans to explore new products to support Bluejay’s biomarker detection program. Furthermore, Bluejay plans to explore strategic opportunities around the specimen biobanks generated from the SYMON I and SYMON II clinical studies.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We were incorporated under the laws of Delaware on March 20, 2015. Our headquarters is located in Acton, Massachusetts.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 4, 2021, the Company formed Bluejay Spinco, LLC, a wholly owned subsidiary of the Company, for purposes of further development of the Company’s ALLEREYE diagnostic test. ALLEREYE is a point-of-care device offering healthcare providers a solution for diagnosing Allergic Conjunctivitis.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Risks and Uncertainties</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Risks related to the Company’s FDA regulatory and clinical trial, Nasdaq listing and going concern status are each described below. In addition, the Company is subject to a number of risks similar to other companies in its industry, including rapid technological change, competition from larger biotechnology companies, availability of raw materials and device components, and dependence on key personnel.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>FDA Regulatory and Clinical Trial Update</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">Our current regulatory strategy is designed to support commercialization of Symphony in the United States pending marketing authorization from the FDA. Previously, our regulatory strategy involved clinical studies involving COVID-19 patients. However, we have shifted our focus away from COVID-19 patients due to a significant decline in the number of COVID-19 related hospitalizations. Pursuant to this revised strategy, we have completed a pilot clinical study (SYMON-1) and plan to begin a clinical study (SYMON-2) to validate the results of the pilot study to support an FDA regulatory submission with an initial indication for risk stratification of hospitalized sepsis patients. We submitted a pre-submission application to the FDA presenting the new study design in May 2023 and participated in a pre-submission meeting on August 11, 2023. At the meeting, the FDA provided feedback on the new study design, determined that the submission of a 510(k) is the appropriate premarket submission pathway, and requested that certain data be provided in the 510(k). Based on this feedback, we determined to proceed on this basis, which considers the FDA’s feedback.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">In the second quarter of 2024, we completed a multicenter SYmphony IL-6 MONitoring Sepsis (“SYMON”) clinical study investigating the role of interleukin-6 (IL-6) in patients diagnosed with sepsis and septic shock. This prospective study assessed the performance of IL-6 upon initial presentation to the intensive care unit (ICU). A primary analysis of the SYMON-I pilot clinical study (registered clinical trial number NCT06181604) highlighted that IL-6 levels within 24 hours of sepsis or septic shock diagnosis and admission to the ICU may predict patient mortality out to 28 days. We will seek to validate these findings in the SYMON-II pivotal study.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">Furthermore, a secondary outcome of the SYMON-I study showed that IL-6 levels within 24 hours of sepsis or septic shock diagnosis and admission to the ICU is a predictor of patient mortality during their hospitalization. Other secondary outcomes showed that lactate and Sequential Organ Failure Assessment (SOFA), standard clinical tests used for sepsis and septic shock patients, were not predictors of patient mortality out to 28 days.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">We believe that the findings underscore the potential importance of IL-6 as a predictor and provide new insights into the potential pathways for improving sepsis outcomes.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">The SYMON II clinical study has three components: (1) collection, freezing, and biobanking of patient samples, (2) measuring IL-6 concentrations in the biobanked samples near the end of patient enrollment or after the patient enrollment has completed, and (3) analysis of the IL-6 data with the patient outcomes to see if the established IL-6 cutoff value has been validated for 28-day all-cause mortality.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">We are planning to initiate the SYMON-II pivotal clinical study in the third quarter of 2024. We plan to use the Symphony IL-6 test to complete the testing in the SYMON-II clinical. If the results are positive, we intend to use SYMON-II as support in a 510(k) application to the FDA in 2025 for the following intended use: “Symphony IL-6 is intended for use to determine the IL-6 concentration as an aid in assessing the cumulative 28-day risk of all-cause mortality in conjunction with other laboratory findings and clinical assessments for patients diagnosed with sepsis or septic shock in the ICU.” We intend to present the SYMON-I and SYMON-II results at future national scientific meetings and publish them in peer-reviewed publications.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">We remain in the development phase of the overall product launch cycle. We currently are experiencing issues with critical materials and pilot production performance that could negatively affect our projected timeline for FDA submission. We are developing plans to improve product performance and ensure supply of these critical materials, and to transfer production and all supply chain activities from the original developer and current supplier of cartridge intermediates (Toray) to an FDA registered contract manufacturer (CMO). We expect that production lots to be used for validation testing to support the FDA submission will be available once a transfer to an FDA registered CMO is completed. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If we are unable to achieve the manufacturing requirements or analytical performance required for FDA clearance, we may pursue utilizing an alternative IL-6 test for the SYMON-II study.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">Our ability to engage in and complete the activities needed for an FDA submission, will be contingent upon us addressing these and other challenges, including possessing and/or raising sufficient capital, remaining a going concern, and producing product capable of supporting our product requirements and meeting analytical validation and clinical validation.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>June 2024 Reverse Stock Split</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 20, 2024, we effected a reverse stock split of our shares of common stock at a ratio of 1-for-8 (the “2024 Reverse Stock Split”). The Company’s common stock continued trading on Nasdaq on a post-split basis under the Company’s existing trading symbol, “BJDX.”</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All of the Company’s historical share and per share information related to issued and outstanding common stock and outstanding options and warrants exercisable for common stock in these financial statements have been adjusted, on a retroactive basis, to reflect the Reverse Stock Split.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Nasdaq Minimum Bid Price Non-Compliance</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our common stock currently is listed for quotation on the Nasdaq Capital Market. We are required to meet specified financial requirements in order to maintain such listing, including a requirement that the bid price for our common stock remain above $1.00, and that the market value of our publicly held securities be at least $1 million.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 28, 2024, we received a notification letter from the Nasdaq Listing Qualifications Staff of the Nasdaq Stock Market LLC (“Nasdaq”) notifying us that the closing bid price for our common stock had been below $1.00 for the previous 30 consecutive business days and that we therefore are not in compliance with the minimum bid price requirement for continued inclusion on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2). The notification has no immediate effect on the listing of our common stock on the Nasdaq Capital Market.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the Nasdaq Listing Rules, we have a period of 180 calendar days to regain compliance. To regain compliance, the closing bid price of our common stock must be at least $1.00 or higher for a minimum of ten consecutive business days, and in such case, Nasdaq will provide us with written confirmation of compliance. If we do not regain compliance by August 26, 2024, we may be eligible for an additional 180 calendar days, provided that we meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for Nasdaq, except the bid price requirement. If we are not eligible or it appears to Nasdaq that we will not be able to cure the deficiency during the second compliance period, Nasdaq will provide written notice to us that our common stock will be subject to delisting. In the event of such notification, we may appeal Nasdaq’s determination to delist our securities, but there can be no assurance that Nasdaq would grant our request for continued listing.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We intend to take all reasonable measures available to us to achieve compliance to allow for continued listing on the Nasdaq Capital Market. However, there can be no assurance that we will be able to regain compliance with the minimum bid price requirement or will otherwise comply with other Nasdaq listing criteria. If our common stock does not regain compliance with the minimum price requirement during the applicable compliance period, we may need to effect a further reverse stock split, whereby shares of our common stock are further consolidated with the intent that the per-share trading price becomes greater than $1.00 per share on a sustained basis sufficient to regain compliance with the applicable Nasdaq requirements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of the close of business on August 13, 2024, the market value of our publicly held common stock (which is our only outstanding class of securities) was approximately $2.1 million, and the most recent closing price of our common stock on the Nasdaq Capital Market was $0.3341 per share. If the market value of our publicly held common stock declines below $1 million, or the closing price of our common stock declines to $0.10 per share or less for 10 consecutive trading days, we would also be subject to Nasdaq delisting proceedings on that basis.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If our common stock is delisted, we may seek to have our common stock quoted on an over-the-counter marketplace, such as on the OTCQX. The OTCQX is not a stock exchange, and if our common stock trades on the OTCQX rather than a securities exchange, there may be significantly less trading volume and analyst coverage of, and significantly less investor interest in, our common stock, which may lead to lower trading prices for our common stock.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">Any potential delisting of our common stock from the Nasdaq Capital Market may have materially adverse consequences to our stockholders, including:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px"> </td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A reduced market price and liquidity with respect to our shares of common stock, which could make our ability to raise new investment capital more difficult;</span></td></tr> <tr style="vertical-align: top"> <td> </td> <td> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td> </td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">limited dissemination of the market price of our common stock;</span></td></tr> <tr style="vertical-align: top"> <td> </td> <td> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td> </td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">limited news coverage;</span></td></tr> <tr style="vertical-align: top"> <td> </td> <td> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td> </td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">limited interest by investors in our common stock;</span></td></tr> <tr style="vertical-align: top"> <td> </td> <td> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td> </td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">volatility of the prices of our common stock, due to low trading volume;</span></td></tr> <tr style="vertical-align: top"> <td> </td> <td> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td> </td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our common stock being considered a “penny stock,” which would result in broker-dealers participating in sales of our common stock being subject to the regulations set forth in Rules 15g-2 through 15g-9 promulgated under the Exchange Act;</span></td></tr> <tr style="vertical-align: top"> <td> </td> <td> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td> </td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">increased difficulty in selling our common stock in certain states due to “blue sky” restrictions; and</span></td></tr> <tr style="vertical-align: top"> <td> </td> <td> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td> </td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">limited ability to issue additional securities or to secure additional financing.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Going Concern Uncertainty</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying unaudited condensed consolidated financial statements were prepared under the assumption that the Company will continue as a going concern, which contemplates that the Company will be able to realize assets and discharge liabilities in the normal course of business.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our operations to date have been funded primarily through equity financings. As of June 30, 2024, the Company had cash and cash equivalents of approximately $8.1 million, and current liabilities of approximately $2.2 million. During the six-month period ended June 30, 2024, the Company’s net cash used in operating activities was approximately $4.1 million. The future viability of the Company is largely dependent on its ability to raise additional capital to finance its operations. The Company expects that it will need to raise additional capital within the next twelve months to continue its operations as the current, cash resources will be sufficient to fund its operations through the first quarter of 2025. Although the Company has been successful in raising capital in the past, there is no assurance that it will be successful in obtaining such additional financing on terms acceptable to the Company, if at all. If the Company is unable to obtain funding, the Company could be forced to delay, reduce or eliminate its research and development program, product development or commercialization efforts, which could adversely affect its business prospects.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "> </p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; ">Accordingly, based on the considerations discussed above, management has concluded there is substantial doubt as to the Company’s ability to continue as a going concern within one year after the date these condensed consolidated financial statements are issued. The Company plans to continue to fundraise. If adequate funds are not available, the Company may require initiating steps to slow cash burn, extending the cash runway until financing can be secured. These condensed consolidated financial statements do not include any adjustments with respect to the carrying amounts of assets and liabilities and their classification that might result from the outcome of this uncertainty.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25pt"><b><i>Basis of Presentation</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25pt; text-align: justify">The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in conformity with generally accepted accounting principles in the United States (“US GAAP”) consistent with those applied in, and should be read in conjunction with, the Company’s audited financial statements and related footnotes for the year ended December 31, 2023, included in the Company’s Annual Report on Form 10-K. The unaudited condensed consolidated financial statements reflect all adjustments, which include only normal recurring adjustments, necessary for the fair presentation of the Company’s financial position as of June 30, 2024, its results of operations and cash flows for the six months ended June 30, 2024, and 2023, in accordance with US GAAP. The unaudited condensed consolidated financial statements do not include all the information and footnotes required by US GAAP for complete financial statements, as allowed by the relevant U.S. Securities and Exchange Commission (“SEC”) rules and regulations; however, the Company believes that its disclosures are adequate to ensure that the information presented is not misleading. The condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiary. All intercompany balances and transactions have been eliminated in consolidation.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25pt; text-align: justify">The results for the three and six months ended June 30, 2024, are not necessarily indicative of the results that may be expected for the fiscal year ending December 31, 2024, or any other interim period within this fiscal year.</p>
CY2024Q2	us-gaap	Securities Held As Collateral At Fair Value SecuritiesHeldAsCollateralAtFairValue	1000000	usd
CY2024Q2	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	1
	bjdx	Trading Price Per Share TradingPricePerShare	1
CY2024Q3	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	0.3341
CY2024Q3	bjdx	Market Value Of Held Common Stock MarketValueOfHeldCommonStock	1000000	usd
CY2024Q3	bjdx	Closing Price Per Share ClosingPricePerShare	0.1
CY2024Q3	bjdx	Number Of Trading Days NumberOfTradingDays	10	pure
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4100000	usd
	bjdx	Going Concern Term GoingConcernTerm	P1Y
	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Use of Estimates</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts and disclosures reported in these condensed consolidated financial statements and accompanying notes. Actual results could differ materially from those estimates. The Company believes judgment is involved in accounting for the fair value-based measurement of stock-based compensation, accruals, and warrants. The Company evaluates its estimates and assumptions as facts and circumstances dictate. As future events and their effects cannot be determined with precision, actual results could differ from these estimates and assumptions, and those differences could be material to the condensed consolidated financial statements.</p>
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	pure
	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	333333	usd
CY2024Q2	bjdx	Fair Value Of Common Stock Issued FairValueOfCommonStockIssued	307563	usd
CY2024Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	1.6299
CY2024Q2	bjdx	Minimum Reduction Percentage MinimumReductionPercentage	0.50	pure
CY2024Q2	us-gaap	Share Price SharePrice	0.326
	bjdx	Closing Price Percentage ClosingPricePercentage	0.20	pure
CY2024Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q2	us-gaap	Payments For Fees PaymentsForFees	743750	usd
CY2024Q2	bjdx	Gross Proceeds Received GrossProceedsReceived	0.085	pure
	bjdx	Total Number Of Securities Offered Percentage TotalNumberOfSecuritiesOfferedPercentage	0.15	pure
CY2024Q1	us-gaap	Warrant Exercise Price Decrease WarrantExercisePriceDecrease	1.2999
CY2024Q1	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P5Y
CY2023Q4	us-gaap	Management Fee Expense ManagementFeeExpense	35000	usd
CY2023Q4	bjdx	Private Placement Warrants Gross Proceeds Percentage PrivatePlacementWarrantsGrossProceedsPercentage	0.01	pure
CY2023Q4	bjdx	Purchase Of Warrants PurchaseOfWarrants	188462	shares
	bjdx	Aggregate Percentage Of Common Stock And Prefunded Warrants AggregatePercentageOfCommonStockAndPrefundedWarrants	0.07	pure
	bjdx	Exercise Percentage ExercisePercentage	1.25	pure
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	18734	shares
CY2023Q1	us-gaap	Stock Issued During Period Shares Employee Benefit Plan StockIssuedDuringPeriodSharesEmployeeBenefitPlan	6546	shares
CY2023Q1	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	57588	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3721	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	292.08
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y6M
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3721	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	292.08
	bjdx	Weighted Average Remaining Contractual Life In Years Outstanding At Ending Balance WeightedAverageRemainingContractualLifeInYearsOutstandingAtEndingBalance	P6Y2M12D
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	3276	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	292.08
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y2M12D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	70.4
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0363	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.0878	pure
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2024Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6010	usd
CY2023Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	27702	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	17884	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	247293	usd
CY2021	bjdx	Related Party Bill Rate Additional Cost Percentage RelatedPartyBillRateAdditionalCostPercentage	0.10	pure
CY2024Q2	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	30609	usd
CY2024Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2834888	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2529457	usd
CY2024Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1281894	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1243716	usd
CY2024Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1552994	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1285741	usd
	us-gaap	Accumulated Depreciation Depletion And Amortization Sale Of Property Plant And Equipment1 AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1	247000	usd
CY2024Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y4M24D
CY2023Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y3M18D
CY2024Q2	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P3Y7M6D
CY2023Q2	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P4Y7M6D
CY2024Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.07	pure
CY2023Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.07	pure
	us-gaap	Operating Lease Payments OperatingLeasePayments	88428	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	84352	usd
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	2403	usd
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	2403	usd
CY2024Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	263402	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	333267	usd
CY2024Q2	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	12787	usd
CY2023Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	15152	usd
CY2024Q2	bjdx	Lease Assets LeaseAssets	276189	usd
CY2023Q4	bjdx	Lease Assets LeaseAssets	348419	usd
CY2024Q2	bjdx	Operating Lease Liabilitys Current OperatingLeaseLiabilitysCurrent	128633	usd
CY2023Q4	bjdx	Operating Lease Liabilitys Current OperatingLeaseLiabilitysCurrent	162990	usd
CY2024Q2	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	4807	usd
CY2023Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	4807	usd
CY2024Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	150777	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	189987	usd
CY2024Q2	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	10477	usd
CY2023Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	12321	usd
CY2024Q2	bjdx	Total Lease Liabilities TotalLeaseLiabilities	294694	usd
CY2023Q4	bjdx	Total Lease Liabilities TotalLeaseLiabilities	370105	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	78632	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	100000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	100000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	25000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	303632	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	24222	usd
CY2024Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	279410	usd
	bjdx	Royalty Payments Net Sales Percentage RoyaltyPaymentsNetSalesPercentage	0.075	pure
	bjdx	Net Sales Of The Cartridges For The Period NetSalesOfTheCartridgesForThePeriod	P10Y
	bjdx	Royalty Rate Percentage RoyaltyRatePercentage	0.50	pure
CY2024Q2	us-gaap	Prepaid Insurance PrepaidInsurance	518880	usd
CY2023Q4	us-gaap	Prepaid Insurance PrepaidInsurance	136342	usd
CY2024Q2	bjdx	Prepaid Vendor Prepaymentscurrent PrepaidVendorPrepaymentscurrent	254819	usd
CY2023Q4	bjdx	Prepaid Vendor Prepaymentscurrent PrepaidVendorPrepaymentscurrent	558959	usd
CY2024Q2	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	186294	usd
CY2023Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	51962	usd
CY2024Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	959993	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	747263	usd
CY2024Q2	bjdx	Accrued Personnel Costs AccruedPersonnelCosts	557722	usd
CY2023Q4	bjdx	Accrued Personnel Costs AccruedPersonnelCosts	566087	usd
CY2024Q2	bjdx	Accrued Goods Received But Unpaid AccruedGoodsReceivedButUnpaid	8175	usd
CY2023Q4	bjdx	Accrued Goods Received But Unpaid AccruedGoodsReceivedButUnpaid	78579	usd
CY2023Q4	bjdx	Accrued Expenses For Cfo Separation Agreement AccruedExpensesForCFOSeparationAgreement	160000	usd
CY2024Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	313220	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	157670	usd
CY2024Q2	bjdx	Accrued Clinical Trial Expenses AccruedClinicalTrialExpenses	240377	usd
CY2024Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	171259	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	154575	usd
CY2024Q2	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	1290753	usd
CY2023Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	1116911	usd
CY2024Q2	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024Q2	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q2	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-22.00
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-41.95
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	127608	shares
CY2024Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	483164	shares
CY2024Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised		usd
CY2024Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised		usd
CY2023Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues		usd
	us-gaap	Other Noncash Expense OtherNoncashExpense		usd
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims		usd
	us-gaap	Asset Impairment Charges AssetImpairmentCharges		usd
	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges		usd
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities		usd
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable		usd
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable		usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts		usd
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation		usd
	bjdx	Fair Value Of Common Stock Issued In Connection With Notes Payable FairValueOfCommonStockIssuedInConnectionWithNotesPayable		usd
	us-gaap	Noncash Or Part Noncash Acquisition Other Assets Acquired1 NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1		usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross		shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
	bjdx	Weighted Average Remaining Contractual Life In Years Exercised WeightedAverageRemainingContractualLifeInYearsExercised
	bjdx	Aggregate Intrinsic Value Granted AggregateIntrinsicValueGranted		usd
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
	bjdx	Weighted Average Remaining Contractual Life In Years Exercised WeightedAverageRemainingContractualLifeInYearsExercised
	bjdx	Aggregate Intrinsic Value Exercised AggregateIntrinsicValueExercised		usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod		shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
	bjdx	Weighted Average Remaining Contractual Life In Years Cancelled And Forfeited WeightedAverageRemainingContractualLifeInYearsCancelledAndForfeited
	bjdx	Aggregate Intrinsic Value Cancelled And Forfeited AggregateIntrinsicValueCancelledAndForfeited		usd
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2024Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1		usd
CY2023Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent		usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour		usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive		usd
CY2024Q2	bjdx	Accrued Expenses For Cfo Separation Agreement AccruedExpensesForCFOSeparationAgreement		usd
CY2023Q4	bjdx	Accrued Clinical Trial Expenses AccruedClinicalTrialExpenses		usd
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Entity Central Index Key EntityCentralIndexKey	0001704287

Files In Submission

Name	View Source	Status
0001213900-24-069110-index-headers.html	Edgar Link	pending
0001213900-24-069110-index.html	Edgar Link	pending
0001213900-24-069110.txt	Edgar Link	pending
0001213900-24-069110-xbrl.zip	Edgar Link	pending
bjdx-20240630.xsd	Edgar Link	pending
ea0211334-10q_bluejay.htm	Edgar Link	pending
ea021133401ex31-1_bluejay.htm	Edgar Link	pending
ea021133401ex31-2_bluejay.htm	Edgar Link	pending
ea021133401ex32-1_bluejay.htm	Edgar Link	pending
ea021133401ex32-2_bluejay.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
bjdx-20240630_cal.xml	Edgar Link	unprocessable
bjdx-20240630_def.xml	Edgar Link	unprocessable
bjdx-20240630_lab.xml	Edgar Link	unprocessable
bjdx-20240630_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
ea0211334-10q_bluejay_htm.xml	Edgar Link	completed
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$BJDX
Bluejay Diagnostics, Inc. Stock $bjdx

2024 Q3 Form 10-Q Financial Statement

#000121390024069110 Filed on August 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BJDX Bluejay Diagnostics, Inc. Stock $bjdx

2024 Q3 Form 10-Q Financial Statement

#000121390024069110 Filed on August 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BJDX
Bluejay Diagnostics, Inc. Stock $bjdx